Develops disease‑modifying therapies for patients with Fragile X Syndrome and Autism Spectrum Disorder, leveraging decades of neuroscience research and the mGluR theory. Aims to develop and market the first approved therapy for Fragile X Syndrome to improve patient outcomes.